Back to Journals » Journal of Inflammation Research » Volume 5

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets

Authors Vega-Carrascal, Reeves E , McElvaney NG

Received 25 May 2012

Accepted for publication 12 July 2012

Published 14 August 2012 Volume 2012:5 Pages 77—87

DOI https://doi.org/10.2147/JIR.S34225

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3



Isabel Vega-Carrascal, Emer P Reeves, Noel G McElvaney

Respiratory Research Division, Department of Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin, Ireland

Abstract: T cell immunoglobulin and mucin-domain (TIM)-containing molecules have emerged as promising therapeutic targets to correct abnormal immune function in several autoimmune and chronic inflammatory conditions. Despite the initial discovery linking TIM-containing molecules and the airway hyperreactivity regulatory locus in mice, there is a paucity of studies on the function of TIM-containing molecules in lung inflammatory disease. Initially, studies were limited to mice models of asthma. More recently however, TIM-containing molecules have been implicated in an ever-expanding list of airway conditions that includes pneumonia, tuberculosis, influenza, sarcoidosis, lung cancer, and cystic fibrosis. This present review discusses the role of TIM-containing molecules and their ligands in the lung, as well as their potential as therapeutic targets in airway disease.

Keywords: T cell immunoglobulin and mucin-domain, inflammation, galectin-9, airway disease

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.